Print Page     Close Window     

SEC Filings

S-3
SEELOS THERAPEUTICS, INC. filed this Form S-3 on 02/01/2019
Entire Document
 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on February 1, 2019.

 

SEELOS THERAPEUTICS, INC.

 

 

 

 

 

 

By:

/s/ Raj Mehra, Ph.D.

 

 

 

   Raj Mehra, Ph.D.
    President and Chief Executive Officer

 

 

POWER OF ATTORNEY

Know All Persons By These Presents, that each person whose signature appears below constitutes and appoints Raj Mehra, Ph.D. his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature

 

Title

 

Date

 

 

 

 

 

/s/ Raj Mehra, Ph.D.

 

President, Chief Executive Officer and Chairman of the Board

 

February 1, 2019

Raj Mehra, Ph.D.

 

(Principal Executive Officer)

 

 

 

 

 

 

 

/s/ Raj Mehra, Ph.D.

 

Interim Chief Financial Officer

 

February 1, 2019

Raj Mehra, Ph.D.

 

(Principal Financial and Accounting Officer)

 

 

 

 

 

 

 

/s/ Brian Lian, Ph.D.

 

Director

 

February 1, 2019

Brian Lian, Ph.D.

 

 

 

 

/s/ Daniel J. O'Connor, J.D.

 

Director

 

February 1, 2019

Daniel J. O'Connor, J.D.

 

 

 

 

/s/ Richard W. Pascoe

 

Director

 

February 1, 2019

Richard W. Pascoe

 

 

 

 

 

/s/ Dr. Robin L. Smith

 

Director

 

February 1, 2019

Dr. Robin L. Smith

 

 

 

 

 

 

 

 

 

 


 


© Apricus Biosciences, Inc.